These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 14605669)
1. Antitumor immunity against bladder cancer induced by ex vivo expression of CD40 ligand gene using retrovirus vector. Kimura T; Ohashi T; Kikuchi T; Kiyota H; Eto Y; Ohishi Y Cancer Gene Ther; 2003 Nov; 10(11):833-9. PubMed ID: 14605669 [TBL] [Abstract][Full Text] [Related]
3. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells. Kikuchi T; Miyazawa N; Moore MA; Crystal RG Cancer Res; 2000 Nov; 60(22):6391-5. PubMed ID: 11103803 [TBL] [Abstract][Full Text] [Related]
4. Induction of antitumor immunity by transduction of CD40 ligand gene and interferon-gamma gene into lung cancer. Noguchi M; Imaizumi K; Kawabe T; Wakayama H; Horio Y; Sekido Y; Hara T; Hashimoto N; Takahashi M; Shimokata K; Hasegawa Y Cancer Gene Ther; 2001 Jun; 8(6):421-9. PubMed ID: 11498762 [TBL] [Abstract][Full Text] [Related]
5. In vivo antitumor effect of CD40L-transduced tumor cells as a vaccine for B-cell lymphoma. Briones J; Timmerman J; Levy R Cancer Res; 2002 Jun; 62(11):3195-9. PubMed ID: 12036933 [TBL] [Abstract][Full Text] [Related]
6. In vivo gene transfer of CD40 ligand into colon cancer cells induces local production of cytokines and chemokines, tumor eradication and protective antitumor immunity. Sun Y; Peng D; Lecanda J; Schmitz V; Barajas M; Qian C; Prieto J Gene Ther; 2000 Sep; 7(17):1467-76. PubMed ID: 11001366 [TBL] [Abstract][Full Text] [Related]
7. Enhanced antitumor immunity derived from a novel vaccine of fusion hybrid between dendritic and engineered myeloma cells. Hao S; Bi X; Xu S; Wei Y; Wu X; Guo X; Carlsen S; Xiang J Exp Oncol; 2004 Dec; 26(4):300-6. PubMed ID: 15627063 [TBL] [Abstract][Full Text] [Related]
8. In vitro activation of cancer patient-derived dendritic cells by tumor cells genetically modified to express CD154. Loskog A; Tötterman TH; Böhle A; Brandau S Cancer Gene Ther; 2002 Oct; 9(10):846-53. PubMed ID: 12224026 [TBL] [Abstract][Full Text] [Related]
9. Intratumoral administration of immature dendritic cells following the adenovirus vector encoding CD40 ligand elicits significant regression of established myeloma. Liu Y; Xia D; Li F; Zheng C; Xiang J Cancer Gene Ther; 2005 Feb; 12(2):122-32. PubMed ID: 15565183 [TBL] [Abstract][Full Text] [Related]
10. Interleukin-21 gene transfection into mouse bladder cancer cells results in tumor rejection through the cytotoxic T lymphocyte response. Furukawa J; Hara I; Nagai H; Yao A; Oniki S; Fujisawa M J Urol; 2006 Sep; 176(3):1198-203. PubMed ID: 16890725 [TBL] [Abstract][Full Text] [Related]
11. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen. Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645 [TBL] [Abstract][Full Text] [Related]
12. T-cell-dependent antitumor effects produced by CD40 ligand expressed on mouse lung carcinoma cells are linked with the maturation of dendritic cells and secretion of a variety of cytokines. Tada Y; O-Wang J; Yu L; Shimozato O; Wang YQ; Takiguchi Y; Tatsumi K; Kuriyama T; Takenaga K; Sakiyama S; Tagawa M Cancer Gene Ther; 2003 Jun; 10(6):451-6. PubMed ID: 12768190 [TBL] [Abstract][Full Text] [Related]
13. Genetically modified dendritic cells prime autoreactive T cells through a pathway independent of CD40L and interleukin 12: implications for cancer vaccines. Wan Y; Bramson J; Pilon A; Zhu Q; Gauldie J Cancer Res; 2000 Jun; 60(12):3247-53. PubMed ID: 10866318 [TBL] [Abstract][Full Text] [Related]